Select Page

Effect of integrated hepatitis C virus treatment on psychological distress in people with substance use disorders
“People with substance use disorders (SUD) have a high prevalence of chronic hepatitis C virus (HCV) infection and mental health disorders. We aimed to assess the impact of integrated HCV treatment on psychological distress measured by Hopkins-symptom-checklist-10 (SCL-10). This multi-center randomized controlled trial evaluated psychological distress as a secondary outcome of integrated HCV treatment (INTRO-HCV trial).”

Atea Pharmaceuticals (AVIR) Reports Positive Initial Data from Phase 2 Study for Hepatitis C Virus
“Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the achievement of two significant clinical milestones from its Hepatitis C Virus (HCV) and COVID-19 programs.”

Why it’s time to make lower-risk injecting equipment more widely available
“When it comes to preventing HIV, the type of syringes that people use to inject drugs makes a difference. But access to lower-risk equipment is limited, a new report reveals”

DAAs Reduce Iron Parameters in Patients with Hepatitis C, Hyperferritinemia
“Statistically significant reductions in serum ferritin, transferrin saturation index, and iron levels were observed after treatment, with hyperferritinemia eradicated in nearly all patients treated with DAAs achieving SVR.”

Eliminating Hepatitis C: A Virus with Unequal Impact
“The legacy and ongoing toll of hep-C remains complicated by racial inequality, income disparity, and stigma.”

FDA approves Florida’s request to import cheaper drugs from Canada
“The US Food and Drug Administration has approved Florida’s request to import prescription drugs from Canada to rein in drug prices in the state. Medicines in Canada can be nearly half the price of US counterparts and some drugs cost almost $400 a pill in Florida. The FDA’s decision could open the door for other states to follow suit. The major policy shift overrides decades of opposition from the US pharmaceutical industry. The industry’s major lobbying group has already indicated it will try to intervene.”

NYC Moves Closer to Eliminating Viral Hepatitis as a Public Health Threat
“January 3, 2024 — The Health Department released its 2022 Hepatitis A, B, and C Annual Report, which includes a summary of 2022 hepatitis A, B, and C surveillance data and programming for New York City. The report also includes updates on progress toward implementing the Health Department and community partners’ Plan to Eliminate Viral Hepatitis as a Major Public Health Threat in New York City by 2030, a set of strategies to reduce the number of new hepatitis B and C infections, improve the health of people with hepatitis B and C, and reduce health inequities related to viral hepatitis infection in New York City, released in December 2021.”